NYSE: SCL · Specialty Chemicals

Stepan (SCL) fair value: undervalued or overvalued?

As of 14 Nov 2026, Faircurve's model values Stepan (SCL) at $61.52 a share. The stock last closed at $66.90, which puts the model's fair value 8.0% below the price. On the model's bands that reads as Fairly valued.

Revalued . Price is the close of 16 Nov 2026. Stepan Co.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$61.52midpoint of 2,000 simulations
Last close$66.90NYSE: SCL
Gap to fair value-8.0%fair value against price
Model verdictFairly valuedevidence grade: Medium

This week, in three parts

What happenedThe run of 14 Nov 2026 moved the fair value from $62.33 to $61.52 (-1.3%). Net debt rose on the latest balance sheet: most of the move.

What the model makes of itThe price of $66.90 is 8.0% above it: Fairly valued, on a medium evidence grade.

What's nextNext report on 22 Feb 2027. Options prices imply a move of about 14% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give SCL?

The calibrated range for SCL over 63 trading days is $57.27 to $78.76. It sits around the last close, and its width comes from the volatility that SCL's own options imply (47% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $44.43 to $81.62. In 41% of the simulations the fair value came out above the price the model ran on.

$28.45$116.06
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $61.52. Dashed line: the last close, $66.90.

Faircurve Insights · 14 Nov 2026

Stepan Company produces and sells specialty and intermediate chemicals to other manufacturers for use in various end products in the United States, France, Poland, the United Kingdom, Brazil, Mexico and internationally.

Faircurve's model put the fair value at $61.52 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $62.33, so the fair value moved -1.3%. The model's reason: "Net debt rose on the latest balance sheet: most of the move." The calibrated range over 63 trading days is $58.59 to $75.69. Ranges built this way held the price 60% of the time at this horizon. The evidence grade is Medium, based on how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. The grade does not say whether the fair value is right.

The model's overall quality score is 37 out of 100, a composite of six factors scored against comparable companies. Growth quality stands out at 88, with trailing revenue growth of 7.0% against a peer median of -2.7%. Profitability scores 5, with ROIC of 4.8% against a peer median of 9.7%. The model compares the company with Minerals Technologies Inc. (MTX), Innospec Inc. (IOSP), H.B. Fuller Company (FUL), Quaker Houghton (KWR) and Hawkins, Inc. (HWKN).

Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does SCL report earnings, and how has the stock reacted?

Stepan's next earnings report is scheduled for 22 Feb 2027. Companies can move their dates.

Options prices on 16 Nov 2026 imply a move of about 10.9% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. SCL's 30 day implied volatility works out to about 13.6% over one month.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across SCL's last 8 reports, ignoring direction, was 7.2%.

0%10%20%no quote2.3%19 Feb '25no quote8.1%30 Jul '25no quote3.2%29 Oct '25no quote21.9%23 Feb '26no quote7.1%28 Apr '26no quote12.2%29 Jul '26no quote7.3%28 Oct '26no quote1.2%4 Nov '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

How does SCL score on business quality?

Stepan's overall quality score is 37 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.54.8%ROIC9.7%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).23-15.24xFCF / net income0.80x
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.887.0%Revenue growth, trailing-2.7%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.70.0%Net buybacks / market value2.7%
Balance sheetNet debt to EBITDA and interest coverage.683.59xNet debt / EBITDA4.46x
StabilityDownside volatility of the EBITDA margin over the last five years.571.0 ptsEBITDA margin downside volatility, 5y3.0 pts

How does SCL compare with similar companies?

The companies in specialty chemicals closest to Stepan in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
MTX Minerals Technologies Inc.$60.57$65.44+8.0%Fairly valued
IOSP Innospec Inc.$79.17$79.13-0.1%Fairly valued
CC The Chemours Company$12.48$13.12+5.1%Low evidence grade
NGVT Ingevity Corporation$60.02$67.46+12.4%Low evidence grade
FUL H.B. Fuller Company$49.00$54.04+10.3%Fairly valued
KWR Quaker Houghton$152.07$131.10-13.8%Fairly valued
WDFC WD-40 Company$226.01$208.49-7.8%Low evidence grade
HWKN Hawkins, Inc.$148.66$136.46-8.2%Fairly valued

What the comparable companies' multiples alone would give for SCL, the peer-implied price, is $46.39 a share on this run. The fair value weighs that against the company's own multiple.

All specialty chemical stocks ranked by gap to fair value

Stepan at a glance

Stepan Company, together with its subsidiaries, produces and sells specialty and intermediate chemicals to other manufacturers for use in various end products in the United States, France, Poland, the United Kingdom, Brazil, Mexico, and internationally.

Market value
$1.5B
Sector
Basic Materials
Industry
Specialty Chemicals
Revenue expected, next twelve months
$2.8B
Consensus revenue growth, next fiscal year
+12.3%
Analysts with estimates
2
Beta to the US market
0.61
First valued by Faircurve
11 Jul 2026

At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. SCL was not among them.

How the fair value is worked out: the model prices Stepan on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for SCL was $62.33. As of 14 Nov 2026 it is $61.52, a change of -1.3%. Net debt rose on the latest balance sheet: most of the move. The model revalues every stock it covers each week, and again after an earnings report.

Questions about Stepan's valuation

Is Stepan stock undervalued or overvalued?

On Faircurve's model, SCL reads as Fairly valued as of 14 Nov 2026. The model's fair value is $61.52 a share against a last close of $66.90, a gap of -8.0%.

What is SCL's fair value?

$61.52 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $44.43 to $81.62.

What price range does the model give SCL?

$57.27 to $78.76 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does Stepan report earnings next?

The next report is scheduled for 22 Feb 2027. Companies can move their dates.

How much has SCL moved on past earnings reports?

Across its last 8 reports the median two session move was 7.2%, ignoring direction. The largest was -21.9% around the report of 23 Feb 2026.

How confident is the model in this valuation?

The model's evidence grade for SCL is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on SCL

The model holds no idea open on SCL today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on SCL with their outcomes. A free account is enough.

Keep reading